News | May 08, 2022
Quality issues force Novartis to suspend production of radioligand therapy medicines
The production suspension impacts commercial and clinical trial supply
The production suspension impacts commercial and clinical trial supply
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The report has estimated 4.74 million deaths for India in 2020 and 2021,
The study, presented at the European Stroke Organisation Conference (ESOC 2022) pinpointed specific groups of bacteria associated with poorer neurological recovery from ischaemic stroke both in the acute phase (24 hours) and after three months
As an industrial partner of the IHU, the Medi-Globe Group is thus further expanding its role as an innovation leader in minimally invasive diagnostics and therapies
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Subscribe To Our Newsletter & Stay Updated
